openPR Logo
Press release

Male Hypogonadism Market by Therapy (Testosterone Replacement therapy and Gonadotropin and Gonadotropin-Releasing Hormones Therapy

02-16-2017 12:15 PM CET | Health & Medicine

Press release from: Market Research Reports. BMR

Male hypogonadism is a medical condition characterized by the inability of the testes to produce sufficient amount of testosterone, which is responsible for the development of secondary sexual characteristics. This results in underdevelopment of muscles, impaired growth of body hair, development of breast tissues, and lack of deepening of the voice.

View Sample Copy of Report @ https://goo.gl/nOpFFu

The global male hypogonadism market was valued at $2,594 million in 2015, and is estimated to reach $3,233 million by 2022, growing at a CAGR of 3.1% during the analysis period. Globally, the prevalence for hypogonadism among men is on a rise at a rapid rate, and according to multiple studies, only 10–15% of patients receive treatment for this condition. Major factors that drive the market growth include high incidence of hypogonadism; rise in geriatric population; growth in awareness of hypogonadism & its treatment options; and increased risk of developing hypogonadism due to increased incidence of chronic lifestyle diseases such as diabetes and obesity. In March 2015, FDA issued cautions & warnings against use of testosterone products as a therapy, and ordered the manufacturers to change labels & add cautions on their packaging. From recent studies conducted by the FDA, there is a high risk of acquiring cardiovascular diseases due to the use of TRT, thus impeding the market growth during the forecast period. However, novel treatment options that are under developmental stage have shown positive results in terms of efficacy, and they are expected to have lesser or no side effects. Therefore, these advancements are anticipated to provide new opportunities in the future.

Enquire here @ https://goo.gl/fGEvsP

The global male hypogonadism market is segmented based on therapy, drug delivery, type, and geography. Based on therapy, it is bifurcated into testosterone replacement therapy (TRT), and gonadotropin and gonadotropin-releasing hormones therapy. Gonadotropin and gonadotropin-releasing hormones therapy is further sub-classified into LH, FSH, human chorionic gonadotropin (hCG), and GnRH. Based on drug delivery, it is classified into topical gels, injectables, transdermal patches, and others. Based on type, it is categorized into Klinefelter's syndrome, Kallmann syndrome, pituitary disorders, and others. Based on geography, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).

MALE HYPOGONADISM MARKET KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market, with current trends and future estimations to elucidate the imminent investment pockets.
It presents a quantitative analysis from 2014 to 2022, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
Extensive analysis by therapy helps in understanding the various types of therapies used for the treatment of hypogonadism.
Comprehensive analysis of geographical regions is provided, which helps in determining the prevailing opportunities in these geographies.
Key players within the market are profiled and their strategies are analyzed thoroughly to determine competitive outlook of the global market.
MALE HYPOGONADISM MARKET KEY MARKET SEGMENTS

BY THERAPY

Testosterone Replacement Therapy
Gonadotropin and Gonadotropin-Releasing Hormones Therapy
Luteinizing Hormone (LH)
Follicle-Stimulating Hormone (FSH)
Human Chorionic Gonadotropin (hCG)
Gonadotropin-Releasing Hormone (GnRH)
BY DRUG DELIVERY

Topical Gels
Injectables
Transdermal Patches
Others
BY TYPE

Klinefelter's Syndrome
Kallmann Syndrome
Pituitary Disorders
Others
BY GEOGRAPHY

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Rest of Europe
Asia-Pacific
Japan
India
China
Rest of Asia-Pacific
LAMEA
Latin America
Middle East
Africa
LIST OF KEY PLAYERS PROFILED IN THE REPORT

AbbVie Inc.
Allergan plc
Astrazeneca plc
Bayer AG.
Eli Lilly and Company Ltd.
Endo International plc.
Merck & Co., Inc.
Ferring
Finox Biotech
IBSA Institut Biochimque SA
Laboratoires Genevrier
Teva Pharmaceutical Industries Ltd.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

Lipocine Inc.
Pfizer Inc.
Aytu Biosciences
Diurnal Group PLC
Hyundai Pharmaceuticals Co Ltd.
Perrigo Company plc
Novus Biologicals, LLC

For Complete Analysis & Puchase Enquire on Male Hypogonadism Market @ http://www.bigmarketresearch.com/request-for-customization/905690

Contact us:
5933 NE Win Sivers Drive,
#205, Portland, OR 97220
United States
Direct : + 1-503-894-6022
Toll Free : + 1-800-910-6452
Email: help@bigmarketresearch.com
Web: http://www.bigmarketresearch.com

With the arsenal of different search reports, we help you here to look and buy research reports that will be helpful to you and your organization. Our research reports have the capability and authenticity to support your organization for growth and consistency.

With the window of opportunity getting open and shut at a speed of light, it has become very important to survive in the market and only the fittest and competent enough can do so. So, we try and provide with latest changes in the market that can suit your needs and help you take decision accordingly.

5933 NE Win Sivers Drive, #205

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Male Hypogonadism Market by Therapy (Testosterone Replacement therapy and Gonadotropin and Gonadotropin-Releasing Hormones Therapy here

News-ID: 439761 • Views: 410

More Releases from Market Research Reports. BMR

Global Price Comparison Websites (PCW) Market Research Report 2017
“Global Price Comparison Websites (PCW) Market Research Report 2017 ” Order This Report by calling BigMarketResearch.com at +1-971-202-1575 For Sample copy of report@ https://goo.gl/tz199z Notes: Production, means the output of Price Comparison Websites (PCW) Revenue, means the sales value of Price Comparison Websites (PCW) This report studies Price Comparison Websites (PCW) in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production,

More Releases for Gonadotropin

Global Chorionic Gonadotropin Market Data Survey Report 2025
Global Chorionic Gonadotropin Market in rate of barrenness related issues, increment in appropriation of hCG in agony the executives and weight reduction, and usage of recombinant innovation are relied upon to move the development of the chg. advertise. Unified Market Research distributed a report, titled, Global Chorionic Gonadotropin Market Market by Technology (Natural Source Extraction and Recombinant Technology), Therapeutic Area (Female Infertility Treatment, Male Hypogonadism, Oligospermic Treatment, and Others), and
Chorionic Gonadotropin Market Report 2018: Segmentation by Product (Human Chorio …
Global Chorionic Gonadotropin market research report provides company profile for Leebio, Kamiya Biomedical Company, Scrippslabs and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides detailed segmentation on the basis of
Human Chorionic Gonadotropin (HCG) Market Share, Opportunity Analysis, & Industr …
Human chorionic gonadotropin hormone (HCG) is a hormone secreted by the placenta after implantation of a fertilized zygote in the uterus. The hormone also supports normal development of an egg and helps in the stimulation of egg release from the ovary. The HCG is mainly used to induce ovulation in the women under infertility treatment. It is also used among males mostly to increase the sperm count and in young
Human Chorionic Gonadotropin (HCG) Market Industry Forecast Till 2026
Human chorionic gonadotropin hormone (HCG) is a hormone secreted by the placenta after implantation of a fertilized zygote in the uterus. The hormone also supports normal development of an egg and helps in the stimulation of egg release from the ovary. The HCG is mainly used to induce ovulation in the women under infertility treatment. It is also used among males mostly to increase the sperm count and in young
Global Chorionic Gonadotropin Market Share Analysis Report 2017 - 2022
Reports on Chorionic Gonadotropin Market Research Report with the global valuation from the year 2017 to 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Chorionic Gonadotropin in these regions, from 2012 to 2022 (forecast), covering North America Europe China Japan Southeast Asia India Get the abstract of report on: https://www.reportsmonitor.com/request-sample/?post=410189 Global Chorionic Gonadotropin market competition by top manufacturers, with production, price, revenue (value) and market share
Global Chronic Gonadotropin Industry Market Research Report 2017
Summary The Global Chronic Gonadotropin Industry 2017 Market Research Report is a professional and in-depth study on the current state of the Chronic Gonadotropin industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Chronic Gonadotropin market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status. Secondly, development policies and plans are discussed as